NASDAQ:SYBX - Synlogic Stock Price, Price Target & More

$13.15 0.00 (0.00 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$13.15
Today's Range$12.96 - $13.4280
52-Week Range$8.76 - $23.00
Volume29,016 shs
Average Volume131,216 shs
Market Capitalization$255.55 million
P/E Ratio-2.24
Dividend YieldN/A
Beta2.22

About Synlogic (NASDAQ:SYBX)

Synlogic logoSynlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975

Debt

Debt-to-Equity Ratio0.01%
Current Ratio9.82%
Quick Ratio9.82%

Price-To-Earnings

Trailing P/E Ratio-2.24
Forward P/E Ratio-4.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.44 million
Price / Sales105.36
Cash FlowN/A
Price / CashN/A
Book Value$3.97 per share
Price / Book3.31

Profitability

EPS (Most Recent Fiscal Year)($5.88)
Net Income$-40,370,000.00
Net MarginsN/A
Return on Equity-50.06%
Return on Assets-45.28%

Miscellaneous

Employees63
Outstanding Shares19,550,000

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

How were Synlogic's earnings last quarter?

Synlogic (NASDAQ:SYBX) posted its quarterly earnings results on Tuesday, March, 20th. The biotechnology company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.07. The biotechnology company had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.11 million. View Synlogic's Earnings History.

When is Synlogic's next earnings date?

Synlogic is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Synlogic.

What price target have analysts set for SYBX?

4 Wall Street analysts have issued twelve-month price targets for Synlogic's stock. Their predictions range from $15.00 to $25.00. On average, they anticipate Synlogic's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Synlogic.

What are Wall Street analysts saying about Synlogic stock?

Here are some recent quotes from research analysts about Synlogic stock:
  • 1. HC Wainwright analysts commented, "Shares When Financing and Leadership Gaps Filled Stock Data 03/16/2018 Price $1.98 Exchange NASDAQ Price Target $4.00 52-Week High $3.50 52-Week Low $1.60 Enterprise Value (M) $149.2 Market Cap (M) $110 Shares Outstanding (M) 55.9 3 Month Avg Volume 501,177 Short Interest (M) 2.74 Balance Sheet Metrics Cash (M) $21.2 Total Debt (M) $60.0 Total Cash/Share $0.38 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q 0.91 (0.22) — 2Q (0.23) (0.18) — 3Q (0.18) (0.17) — 4Q (0.29) (0.16) — FY 0.21 (0.73) (0.39) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 29.5 10.6 — 2Q 8.7 11.9 — 3Q 11.3 13.1 — 4Q 12.5 14.6 — FY 62.0 50.2 73.3 4 3.5 3 2.5 2 1.5 MAR- 17 J UL- 17 NOV- 17 MAR- 18 4 3 2 1 0 Vol. (mil) Price Another solid Belbuca growth quarter; expect near-term CEO and recapitalization." (3/19/2018)
  • 2. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (1/31/2018)

Are investors shorting Synlogic?

Synlogic saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 539,697 shares, a decline of 43.5% from the March 30th total of 955,244 shares. Based on an average daily trading volume, of 96,890 shares, the short-interest ratio is presently 5.6 days. Approximately 4.0% of the company's stock are sold short.

Who are some of Synlogic's key competitors?

Who are Synlogic's key executives?

Synlogic's management team includes the folowing people:
  • Dr. José Carlos Gutierrez-Ramos, Pres, CEO & Director
  • Mr. Paul Francis Miller Ph.D., Chief Scientific Officer
  • Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Chief Medical Officer
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. Dean A. Falb Ph.D., Co-Founder & CTO (Age 51)

Has Synlogic been receiving favorable news coverage?

News coverage about SYBX stock has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synlogic earned a news impact score of 0.04 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $13.15.

How big of a company is Synlogic?

Synlogic has a market capitalization of $255.55 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]


MarketBeat Community Rating for Synlogic (SYBX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synlogic (NASDAQ:SYBX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Synlogic in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 52.09%. The high price target for SYBX is $25.00 and the low price target for SYBX is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 3.002.802.672.33
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.00$19.00$19.6667$19.50
Price Target Upside: 52.09% upside93.68% upside93.38% upside4.11% upside

Synlogic (NASDAQ:SYBX) Consensus Price Target History

Price Target History for Synlogic (NASDAQ:SYBX)

Synlogic (NASDAQ:SYBX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018HC WainwrightReiterated RatingBuy$20.00HighView Rating Details
4/9/2018Piper JaffrayReiterated RatingBuy$15.00LowView Rating Details
11/27/2017WedbushInitiated CoverageOutperform$20.00MediumView Rating Details
9/19/2017Leerink SwannInitiated CoverageOutperform -> Outperform$25.00LowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$14.00LowView Rating Details
9/22/2016CitigroupLower Price TargetNeutral$31.50 -> $14.00N/AView Rating Details
9/21/2016OppenheimerDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Synlogic (NASDAQ:SYBX) Earnings History and Estimates Chart

Earnings by Quarter for Synlogic (NASDAQ:SYBX)

Synlogic (NASDAQ:SYBX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.69)
2019 EPS Consensus Estimate: ($3.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.74)($0.62)($0.66)
Q2 20183($0.79)($0.58)($0.66)
Q3 20183($0.83)($0.58)($0.67)
Q4 20183($0.87)($0.56)($0.69)
Q1 20191($0.69)($0.69)($0.69)
Q2 20191($0.75)($0.75)($0.75)
Q3 20191($0.78)($0.78)($0.78)
Q4 20191($0.83)($0.83)($0.83)

Synlogic (NASDAQ SYBX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.73)N/AView Earnings Details
3/20/2018Q4 2017($0.81)($0.74)$0.11 million$0.11 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.50)($1.66)$0.10 million$0.11 millionViewN/AView Earnings Details
8/4/2017Q2 2017($3.15)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.84)ViewN/AView Earnings Details
3/15/2017Q4 2016($2.94)ViewN/AView Earnings Details
11/10/2016Q3 2016($2.24)($1.82)ViewN/AView Earnings Details
8/15/2016Q2 2016($3.01)($1.89)ViewN/AView Earnings Details
5/12/2016Q1 2016($3.01)($2.24)ViewN/AView Earnings Details
11/13/2015Q3 2015($2.17)($0.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Synlogic (NASDAQ:SYBX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Synlogic (NASDAQ SYBX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 55.53%
Insider Trading History for Synlogic (NASDAQ:SYBX)
Insider Trading History for Synlogic (NASDAQ:SYBX)

Synlogic (NASDAQ SYBX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2016Jon IrvinVPSell280$1.43$400.407,625View SEC Filing  
11/1/2016Jon IrvinVPSell280$1.28$358.408,055View SEC Filing  
10/11/2016Jon IrvinVPSell150$1.83$274.508,335View SEC Filing  
10/3/2016Jon IrvinVPSell250$1.93$482.508,485View SEC Filing  
10/6/2015Michael PowellDirectorBuy857,142$7.00$5,999,994.00View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Synlogic (NASDAQ SYBX) News Headlines

Source:
DateHeadline
Synlogic (SYBX) Receives Fast-Track Designation for SYNB1618Synlogic (SYBX) Receives Fast-Track Designation for SYNB1618
www.streetinsider.com - April 25 at 4:27 PM
HC Wainwright Reiterates "Buy" Rating for Synlogic (SYBX)HC Wainwright Reiterates "Buy" Rating for Synlogic (SYBX)
www.americanbankingnews.com - April 17 at 7:39 AM
Synlogic (SYBX) Given Average Recommendation of "Hold" by BrokeragesSynlogic (SYBX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 14 at 3:31 AM
Zacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Quarterly Sales of $210,000.00Zacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Quarterly Sales of $210,000.00
www.americanbankingnews.com - April 14 at 1:47 AM
Zacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Earnings of -$0.75 Per ShareZacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - April 12 at 11:14 PM
Q2 2018 EPS Estimates for Synlogic (SYBX) Boosted by Piper JaffrayQ2 2018 EPS Estimates for Synlogic (SYBX) Boosted by Piper Jaffray
www.americanbankingnews.com - April 11 at 8:41 AM
Just How Smart Is Smart Medicine? MIT Scientists Are About To Find Out.Just How Smart Is Smart Medicine? MIT Scientists Are About To Find Out.
www.forbes.com - April 10 at 4:17 PM
Synlogic (SYBX) vs. Viking Therapeutics (VKTX) Head-To-Head AnalysisSynlogic (SYBX) vs. Viking Therapeutics (VKTX) Head-To-Head Analysis
www.americanbankingnews.com - April 10 at 9:16 AM
Synlogics (SYBX) "Buy" Rating Reaffirmed at Piper JaffraySynlogic's (SYBX) "Buy" Rating Reaffirmed at Piper Jaffray
www.americanbankingnews.com - April 9 at 11:35 AM
Synlogic Announces Registered Direct Offering of Common StockSynlogic Announces Registered Direct Offering of Common Stock
finance.yahoo.com - April 6 at 10:14 AM
HC Wainwright Analysts Give Synlogic (SYBX) a $20.00 Price TargetHC Wainwright Analysts Give Synlogic (SYBX) a $20.00 Price Target
www.americanbankingnews.com - April 4 at 8:04 AM
Analysts Offer Predictions for Synlogics Q1 2018 Earnings (SYBX)Analysts Offer Predictions for Synlogic's Q1 2018 Earnings (SYBX)
www.americanbankingnews.com - April 4 at 7:32 AM
Synlogic (SYBX) Doses First Patient in Phase 1b/2a Trial of SYNB1020Synlogic (SYBX) Doses First Patient in Phase 1b/2a Trial of SYNB1020
www.streetinsider.com - April 3 at 10:01 AM
Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with CirrhosisSynlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis
finance.yahoo.com - April 2 at 10:10 AM
Synlogic (SYBX) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowSynlogic (SYBX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:16 PM
 Brokerages Expect Synlogic Inc (SYBX) Will Post Quarterly Sales of $240,000.00 Brokerages Expect Synlogic Inc (SYBX) Will Post Quarterly Sales of $240,000.00
www.americanbankingnews.com - March 29 at 10:20 AM
Synlogic Inc Forecasted to Earn FY2018 Earnings of ($2.35) Per Share (SYBX)Synlogic Inc Forecasted to Earn FY2018 Earnings of ($2.35) Per Share (SYBX)
www.americanbankingnews.com - March 26 at 1:26 AM
Synlogic Inc (SYBX) to Post Q1 2018 Earnings of ($0.74) Per Share, Wedbush ForecastsSynlogic Inc (SYBX) to Post Q1 2018 Earnings of ($0.74) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 26 at 1:02 AM
Synlogic Inc Expected to Post Q1 2018 Earnings of ($0.63) Per Share (SYBX)Synlogic Inc Expected to Post Q1 2018 Earnings of ($0.63) Per Share (SYBX)
www.americanbankingnews.com - March 23 at 7:14 AM
Synlogic to Present at the 17th Annual Needham Healthcare ConferenceSynlogic to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 4:11 PM
Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateSynlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 20 at 4:09 PM
Synlogic to Present Data at the American Association for Cancer Research 2018 Annual MeetingSynlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - March 20 at 9:54 AM
Synlogic Inc (SYBX) Receives Average Rating of "Hold" from AnalystsSynlogic Inc (SYBX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 20 at 3:34 AM
Synlogic (SYBX) Receives New Coverage from Analysts at HC WainwrightSynlogic (SYBX) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - March 19 at 11:34 AM
Why Synlogic (SYBX) Might Surprise This Earnings SeasonWhy Synlogic (SYBX) Might Surprise This Earnings Season
finance.yahoo.com - March 19 at 9:51 AM
Q1 2018 Earnings Forecast for Synlogic Inc (SYBX) Issued By WedbushQ1 2018 Earnings Forecast for Synlogic Inc (SYBX) Issued By Wedbush
www.americanbankingnews.com - March 16 at 7:56 AM
Synlogic Inc (SYBX) Expected to Earn FY2022 Earnings of ($1.17) Per ShareSynlogic Inc (SYBX) Expected to Earn FY2022 Earnings of ($1.17) Per Share
www.americanbankingnews.com - March 15 at 2:52 PM
Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic DisordersSynlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders
finance.yahoo.com - March 12 at 10:33 AM
$110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter$110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter
www.americanbankingnews.com - March 11 at 5:38 AM
Contrasting Synlogic (SYBX) and Auxilium Pharmaceuticals (AUXL)Contrasting Synlogic (SYBX) and Auxilium Pharmaceuticals (AUXL)
www.americanbankingnews.com - March 10 at 4:17 PM
Synlogic Inc (SYBX) Given Consensus Rating of "Hold" by BrokeragesSynlogic Inc (SYBX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 23 at 3:16 AM
 Analysts Expect Synlogic Inc (SYBX) to Announce -$0.79 Earnings Per Share Analysts Expect Synlogic Inc (SYBX) to Announce -$0.79 Earnings Per Share
www.americanbankingnews.com - February 21 at 1:28 AM
Changes to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industryChanges to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry
finance.yahoo.com - February 20 at 9:15 AM
Synlogic (SYBX) versus Argos Therapeutics (ARGS) Critical ReviewSynlogic (SYBX) versus Argos Therapeutics (ARGS) Critical Review
www.americanbankingnews.com - February 19 at 1:20 PM
Synlogic (SYBX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowSynlogic (SYBX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:25 PM
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ MedicineSynlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ Medicine
finance.yahoo.com - February 13 at 8:59 AM
Head to Head Survey: Synlogic (SYBX) and ChemoCentryx (CCXI)Head to Head Survey: Synlogic (SYBX) and ChemoCentryx (CCXI)
www.americanbankingnews.com - February 11 at 11:02 PM
Synlogic (SYBX) versus Baxalta (BXLT) Head to Head SurveySynlogic (SYBX) versus Baxalta (BXLT) Head to Head Survey
www.americanbankingnews.com - February 10 at 7:24 AM
Synlogic (SYBX) versus Novus Therapeutics (NVUS) Head to Head AnalysisSynlogic (SYBX) versus Novus Therapeutics (NVUS) Head to Head Analysis
www.americanbankingnews.com - February 8 at 5:22 PM
Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceSynlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 4:32 PM
Synlogic (SYBX) Downgraded to Strong Sell at ValuEngineSynlogic (SYBX) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 11:46 AM
-$0.79 EPS Expected for Synlogic Inc (SYBX) This Quarter-$0.79 EPS Expected for Synlogic Inc (SYBX) This Quarter
www.americanbankingnews.com - February 4 at 1:18 AM
Synlogic Announces Underwriters’ Option Exercise in FullSynlogic Announces Underwriters’ Option Exercise in Full
finance.yahoo.com - January 31 at 4:40 PM
Synlogic (SYBX) Stock Rating Lowered by Zacks Investment ResearchSynlogic (SYBX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 31 at 12:10 PM
Financial Comparison: Synlogic (SYBX) versus Cesca Therapeutics (KOOL)Financial Comparison: Synlogic (SYBX) versus Cesca Therapeutics (KOOL)
www.americanbankingnews.com - January 31 at 3:44 AM
Synlogic (SYBX) Receives New Coverage from Analysts at Piper Jaffray CompaniesSynlogic (SYBX) Receives New Coverage from Analysts at Piper Jaffray Companies
www.americanbankingnews.com - January 29 at 7:32 PM
Synlogic Inc (SYBX) Receives Consensus Recommendation of "Hold" from AnalystsSynlogic Inc (SYBX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 29 at 9:24 AM
Peregrine Pharmaceuticals (CDMO) versus Synlogic (SYBX) Head-To-Head SurveyPeregrine Pharmaceuticals (CDMO) versus Synlogic (SYBX) Head-To-Head Survey
www.americanbankingnews.com - January 28 at 5:14 PM
Synlogic Announces Pricing of Public Offering of Common StockSynlogic Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 24 at 9:24 AM
Synlogic Announces Proposed Public Offering of Common StockSynlogic Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 23 at 4:15 PM

SEC Filings

Synlogic (NASDAQ:SYBX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Synlogic (NASDAQ:SYBX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Synlogic (NASDAQ SYBX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.